Option Care Health (NASDAQ:OPCH) Shares Gap Up – Here’s Why

Shares of Option Care Health, Inc. (NASDAQ:OPCH) gapped up before the market opened on Monday . The stock had previously closed at $23.99, but opened at $27.48. Option Care Health shares last traded at $26.36, with a volume of 535,887 shares trading hands.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on OPCH shares. Bank of America raised shares of Option Care Health from a “neutral” rating to a “buy” rating and raised their price objective for the company from $26.00 to $33.00 in a research note on Monday. Truist Financial cut their price target on Option Care Health from $41.00 to $34.00 and set a “buy” rating for the company in a research note on Friday, November 1st. UBS Group began coverage on Option Care Health in a research note on Thursday, December 5th. They issued a “neutral” rating and a $26.00 price objective for the company. JMP Securities reiterated a “market outperform” rating and set a $30.00 price target (down previously from $31.00) on shares of Option Care Health in a report on Friday, January 10th. Finally, The Goldman Sachs Group cut Option Care Health from a “buy” rating to a “neutral” rating and dropped their price objective for the company from $38.00 to $27.00 in a research note on Monday, November 4th. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $29.86.

Option Care Health Trading Up 3.6 %

The company has a debt-to-equity ratio of 0.77, a current ratio of 1.73 and a quick ratio of 1.32. The company has a market capitalization of $4.89 billion, a P/E ratio of 24.13, a price-to-earnings-growth ratio of 2.43 and a beta of 1.31. The firm has a fifty day moving average price of $23.33 and a 200-day moving average price of $27.70.

Insiders Place Their Bets

In related news, Director Harry M. Jansen Kraemer, Jr. acquired 43,000 shares of the stock in a transaction on Friday, November 8th. The shares were acquired at an average price of $22.54 per share, with a total value of $969,220.00. Following the completion of the transaction, the director now owns 326,334 shares in the company, valued at approximately $7,355,568.36. The trade was a 15.18 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 0.64% of the company’s stock.

Institutional Investors Weigh In On Option Care Health

Several large investors have recently modified their holdings of OPCH. American Century Companies Inc. lifted its stake in Option Care Health by 0.5% in the second quarter. American Century Companies Inc. now owns 1,154,215 shares of the company’s stock valued at $31,972,000 after purchasing an additional 5,614 shares during the last quarter. Federated Hermes Inc. lifted its position in shares of Option Care Health by 5.5% during the 2nd quarter. Federated Hermes Inc. now owns 20,621 shares of the company’s stock valued at $571,000 after buying an additional 1,073 shares during the last quarter. Oppenheimer Asset Management Inc. grew its stake in shares of Option Care Health by 15.4% during the 2nd quarter. Oppenheimer Asset Management Inc. now owns 65,075 shares of the company’s stock worth $1,803,000 after acquiring an additional 8,695 shares during the period. Envestnet Asset Management Inc. increased its holdings in Option Care Health by 2.8% in the 2nd quarter. Envestnet Asset Management Inc. now owns 231,315 shares of the company’s stock worth $6,407,000 after acquiring an additional 6,283 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA bought a new stake in Option Care Health in the 2nd quarter valued at about $68,003,000. Hedge funds and other institutional investors own 98.05% of the company’s stock.

About Option Care Health

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn’s disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.